Reverse redistribution of Tc-99m-tetrofosmin in exercise myocardial SPECT in patients with hypertrophic cardiomyopathy

Annals of Nuclear Medicine

Volumn 12, Issue 5, 1998, Pages 287-292

  Sugihara, Hiroki ^a,b   Taniguchi, Yoko ^b   Kinoshita, Noriyuki ^b   Nakamura, Tomoki ^b   Hirasaki, Satoshi ^b   Azuma, Akihiro ^b   Ushijima, Yo ^a   Okuyama, Chio ^a   Nakagawa, Masao ^b   Maeda, Tomoho ^a  

^a Department of Radiology ^*

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Hypertrophic cardiomyopathy; Myocardial ischemia; Reverse redistribution; Tc 99m tetrofosmin

Indexed keywords

TECHNETIUM 99M; TETROFOSMIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; EXERCISE; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HEART VENTRICLE SIZE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 18144448245     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03164915     Document Type: Article

References (21)

1. Tamaki N, Takahashi N, Kawamoto M, Torizuka T, Tadamura E, Yonekura Y, et al. Myocardial tomography using technetium-99m-tetrofosmin to evaluate coronary artery disease. J Nucl Med 35: 594-600, 1994.
2. Sridhara BS, Braat S, Rigo P, Itti R, Cload P, Lahiri A, et al. Comparison of myocardial perfusion imaging with technetium-99m tetrofosmin versus thallium-201 in coronary artery disease. Am J Cardiol 72: 1015-1019, 1993.
3. Jain D, Wackers FJT, Mattere J, McMahon M, Sinusas AJ, Zaret BL. Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med 34: 1254-1259, 1993.
4. 211Tl imaging and coronary angiography in a phase III multicenter trial. Circulation 91: 313-319, 1995.
5. 99mTc-tetrofosmin. KAKU IGAKU (Jpn J Nucl Med) 34: 45-48, 1997.
6. Nakajima K, Taki J, Shuke N, Bunko H, Takata S. Hisada K. Myocardial perfusion imaging and dynamic analysis with technetium-99m-tetrofosmin. J Nucl Med 34: 1478-1484, 1993.
7. Sugihara H, Kinosihta N, Adachi Y, Taniguchi Y, Ohtsuki K, Hirasaki S, et al. Early and delayed Tc-99m-tetrofosmin myocardial SPECT in patients with left bundle branch block. Ann Nucl Med 12: 281-286, 1998.
8. O'Gara PT, Bonow RO, Maron BJ, Damske BA, Van Lingen A, Bacharach SL, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 76: 1214-1223, 1987.
9. Udelson JE, Bonow RO, O'Gara PT, Maron BJ, Van Lingen A, Bacharach SL, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 79: 1052-1060, 1989.
10. Taniguchi Y, Sugihara H, Terada K, Ito K, Ohtsuki K, Shiga K, et al. Myocardial ischemia and abnormality of cardiac sympathetic nervous function in apical hypertrophic cardiomyopathy. J Cardiol 24: 293-298, 1994.
11. Canon III RO, Rosing DR, Maron BJ, Leon MB, Bonow RO, Watson RM, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 71: 234-243, 1985.
12. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 22: 796-804, 1993.
13. 201Tl myocardial scintigarphy. KAKU IGAKU (Jpn J Nucl Med) 31: 309-318, 1994.
14. Kuribayashi T, Roberts WC. Myocardial disarray at Junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol 70: 1333-1340, 1992.
15. Thompson DS, Naqvi N, Juul SM, Swanton RH, Coltart DJ, Jenkins BS, et al. Effects of propranolol on myocardial oxygen consumption: substrate extraction and hemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J 44: 488-498, 1980.
16. Weiss MB, Ellis K, Sciacca RR, Johnson LL, Schmidt DH, Cannon PJ. Myocardial blood flow in congestive and hypertrophic cardiomyopathy. Relationship to peak wall stress and mean velocity of circumferential fiber shortening. Circulation 54: 484-494, 1976.
17. Pitcher D, Wainwright R, Maisy M, Curry P, Sowton E. Assessment of chest pain in hypertrophic cardiomyopathy using exercise Thallium-201 myocardial scintigraphy. Br Heart J 44: 650-656, 1980.
18. Cannon III RO, Dilsizian V, O'Gara PT, Udelson JE, Schenke WH, Quyyumi A, et al. Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 83: 1660-1667, 1991.
19. Platts EA, North TL, Pickett RD, Kelly JD. Mechanism of uptake of technetium-tetrofosmin. I: uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol 2: 317-326, 1995.
20. Younes A, Songadele JA, Maublant J, Platts E, Pickett R, Veyre A. Mechanism of uptake of technetium-tetrofosmin. II: uptake into isolated adult rat heart mitochondria. J Nucl Cardiol 2: 327-333, 1995.
21. 123I-labeled 15-(p-iodophenyl)-3R,S-Methyl-pentadecanoic acid in hypertrophic cardiomyopathy with asymmetric septal hypertrophy. KAKU IGAKU (Jpn J Nucl Med) 32: 377-385, 1995.